These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 27114562)

  • 21. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
    Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
    J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts.
    Baganz L; Richter A; Albrecht K; Schneider M; Burmester GR; Zink A; Strangfeld A
    Semin Arthritis Rheum; 2019 Jun; 48(6):976-982. PubMed ID: 30316460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs: Results of the GO-MORE study in the Polish population.
    Jeka S; Batko B; Korkosz M; Majdan M; Kwiatkowska B; Dankiewicz-Fares I; Sobiecki JM; Samborski W
    Adv Clin Exp Med; 2018 Apr; 27(4):493-499. PubMed ID: 29558044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity.
    Tymms K; Zochling J; Scott J; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Roberts L; Arnold M; Littlejohn G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):190-6. PubMed ID: 23983001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study.
    Perrotta FM; De Socio A; Scriffignano S; Lubrano E
    Clin Rheumatol; 2018 Jun; 37(6):1449-1455. PubMed ID: 29468339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
    Aramaki T; Kawakami A; Iwamoto N; Fujikawa K; Kawashiri SY; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Furuyama M; Matsuoka N; Ueki Y; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(6):652-6. PubMed ID: 19787419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.
    Pomirleanu C; Ancuta C; Miu S; Chirieac R
    Clin Rheumatol; 2013 May; 32(5):665-70. PubMed ID: 23292520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.
    Wakabayashi H; Inada H; Nishioka Y; Hasegawa M; Nishioka K; Sudo A
    Drugs R D; 2017 Mar; 17(1):233-239. PubMed ID: 28025727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.
    Durez P; Pavelka K; Lazaro MA; Garcia-Kutzbach A; Moots RJ; Amital H; Govoni M; Vastesaeger N
    Clin Rheumatol; 2018 May; 37(5):1417-1420. PubMed ID: 29611083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
    Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
    Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.